Dianthus Therapeutics, Inc. DNTH
Set alert
84.32 USD +2.07 +2.52%
As of Nov 3, 1:12 PM ET
82.24 Day range 86.17
33.20 52-week range 115.96
- YTD
- +104.61%
- 1 year
- +147.78%
- Open
- 83.21
- Prev close
- 82.25
- Mkt cap
- 4.71B
- Vol
- 134.03K
- Avg vol
- 813.26K
- EPS
- -4.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 82.24
- High
- 86.17
- Forward P/E
- -17.84
- Beta
- 0.26
- Short ratio
- 9.16
- Inst. own
- 129.89%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 92.76
- 200-d avg
- 85.03
- 1y target
- 139.06
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 139.06 +64.9% upside
Now 84.32
- Target (low)
- 113.00
- Target (mean)
- 139.06
- Target (high)
- 200.00
Ratings (0m) 18 18 buy · 0 hold · 0 sell
- Strong buy1
- Buy17
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 17
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.94865 | -1.13 – -0.3929 | -0.97 | +2.2% | 388.66K | -1.8% | 10 |
| Next quarter | -1.11 | -1.36 – -0.9841 | -1.43 | +22.3% | 309.11K | +8.8% | 10 |
| Current year | -3.81 | -4.10 – -3.43 | -4.20 | +9.2% | 1.92M | -5.8% | 11 |
| Next year | -4.61 | -5.77 – -3.47 | -3.81 | -20.9% | 1.82M | -5.0% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Roth Capital | Initiated | — | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 11, 2026 | JP Morgan | Initiated | — | Overweight |
| Sep 4, 2026 | Citigroup | Initiated | — | Buy |
| Aug 6, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 5, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 3, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 9, 2026 | Wolfe Research | Initiated | — | Outperform |
| Mar 19, 2026 | Wells Fargo | Initiated | — | Overweight |
| Mar 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Raymond James | Upgrade | Outperform | Strong Buy |
| Mar 10, 2026 | Baird | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Clear Street | Maintained | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 9, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 9, 2026 | Truist Securities | Maintained | Buy | Buy |
| Mar 4, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 11, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Feb 2, 2026 | Jefferies | Maintained | Buy | Buy |
| Jan 8, 2026 | Truist Securities | Maintained | Buy | Buy |
| Dec 22, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 6, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Oct 14, 2025 | Truist Securities | Initiated | — | Buy |
| Sep 17, 2025 | Clear Street | Initiated | — | Buy |
| Sep 12, 2025 | Stifel | Maintained | Buy | Buy |
| Sep 12, 2025 | Wedbush | Maintained | Outperform | Outperform |